Which generation is the Asiminib targeted drug?

Aximini targeted drug is the third generation targeted drug. Asciminib (Asciminib) is a kinase inhibitor developed and produced by Novartis. It is mainly targeted at the treatment of chronic myeloid leukemia (CML). It can effectively inhibit ABL-kinase activity and has significant therapeutic effects on Ph+ CML patients in the chronic phase (Ph+ CML-CP) and Ph+ CML patients with T315I genetic differences (mutation) in CP.

In the treatment of leukemia, targeted drugs are usually divided into different generations based on their development time and mechanism of action. Representative drugs of the first generation TKIs (tyrosine kinase inhibitors) include imatinib (Gleevec), and representative drugs of the second generation TKIs include bosutinib (Bosulif), dasatinib (Sprycel) and nilotinib (Tasigna). As an ABL1 inhibitor, aximinib is classified as a third-generation TKI together with ponatinib (Iclusig).

The dosage specifications of Aceminib include20mg 60 tablets/box and 40mg 60 tablets/box, suitable for patients aged 18 and above. The drug was first approved for marketing by the U.S. Food and Drug Administration (FDA) in January 2021, but it has not yet been launched in mainland China.

As a third-generation TKIAximini has demonstrated its unique advantages in the treatment of leukemia. It not only inhibits ABL-kinase activity, but also specifically targets the T315I mutation, providing a new treatment option for patients who have been treated with two or more tyrosine kinase inhibitors but failed to respond.

In summary, as a third-generation TKI, aximini targeted drug has significant therapeutic effects and unique advantages in the treatment of chronic myeloid leukemia, providing new treatment hope and options for leukemia patients.